WO2013171668A1 - Liposomes containing prostaglandin e1 (pge1) and a plant oestrogen, formulations for topical use containing them and their use - Google Patents

Liposomes containing prostaglandin e1 (pge1) and a plant oestrogen, formulations for topical use containing them and their use Download PDF

Info

Publication number
WO2013171668A1
WO2013171668A1 PCT/IB2013/053912 IB2013053912W WO2013171668A1 WO 2013171668 A1 WO2013171668 A1 WO 2013171668A1 IB 2013053912 W IB2013053912 W IB 2013053912W WO 2013171668 A1 WO2013171668 A1 WO 2013171668A1
Authority
WO
WIPO (PCT)
Prior art keywords
liposomes
liposomes according
formulations
oestrogen
plant
Prior art date
Application number
PCT/IB2013/053912
Other languages
French (fr)
Inventor
Giovanni Brotzu
Giuseppe BROTZU
Original Assignee
Giovanni Brotzu
Brotzu Giuseppe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giovanni Brotzu, Brotzu Giuseppe filed Critical Giovanni Brotzu
Priority to EP13731920.8A priority Critical patent/EP2849714A1/en
Publication of WO2013171668A1 publication Critical patent/WO2013171668A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to the field of pharmaceutical and cosmetic formulations for topical use containing liposomes, in particular for the treatment of alopecia and for hair regrowth in general.
  • Hair loss is an extremely widespread phenomenon affecting both men and women, caused by various factors such as stress, diet, seasonal changes, hereditary factors, etc.
  • liposomes encapsulating PGE1 in combination with a plant oestrogen and possibly a compound capable of increasing the cationic power of the liposome
  • This invention makes available new pharmacological and/or cosmetic products for the treatment of baldness and hair loss comprising liposomes, encapsulating Prostaglandin E1 (PGE1 ) in combination with a plant oestrogen and possibly a compound capable of increasing the cationic power of the liposome.
  • PGE1 Prostaglandin E1
  • the liposomes according to the invention are constituted by a phospholipid vesicle containing a core of aqueous solution.
  • the phospholipids that constitute the wall of the vesicle are natural or synthetic phospholipids, given their high biocompatibility and the absence of toxicity.
  • Phospholipids that can be used according to the invention are for example: phosphatidylcholine (lecithin), phosphatidylethano!amine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), palmitoyl-stearoylphosphatidyicholine, sphingomyelin, and the like.
  • DMPC dimyristoylphosphatidylcholine
  • DPPC dipalmitoylphosphatidylcholine
  • DSPC distearoylphosphatidylcholine
  • palmitoyl-stearoylphosphatidyicholine palmitoyl-stearoylphosphatidyicholine
  • sphingomyelin and
  • Plant oestrogens shall for example mean: equol and isoflavones in general, such as for example: genistein, daidzein, glycitein.
  • the function of the compound capable of increasing the cationic power of the liposome is to increase adhesiveness and to also facilitate the endothelial cell metabolism of the micro capillaries; compounds useful for this purpose are, for example, essential amino acids or carnitine, which is also a fatty acid carrier and allows the mitochondria to use them for the production of ATP.
  • the liposomes can further comprise additives that serve as stabilisers or as modifiers of the surface charge, such as for example cholesterol, cholesterol sulphate and the like.
  • the liposomes according to the present invention can be prepared by simply mixing solutions of the various components in organic solvent and water, sonicating the mixture thus obtained for the required time.
  • the organic solvent as indicated above is preferably ethanol.
  • the mixtures constituted by the solutions of the various components can be sonicated in the organic solvent alone (for example, ethanol) with the organic solvent then being evaporated and re-suspended with an aqueous solution.
  • organic solvent for example, ethanol
  • the outer surface of the liposomes can be coated with hydrophilic polymers such as for example polylysine, polyornithine, fibronectin and mixtures thereof; preferred is polylysine, which also has bactericidal properties, thus preventing possible infections.
  • hydrophilic polymers such as for example polylysine, polyornithine, fibronectin and mixtures thereof; preferred is polylysine, which also has bactericidal properties, thus preventing possible infections.
  • Said coating is obtained by treating the liposomes as described above with an aqueous solution of the hydrophilic polymer as defined above, for example by “dropping" the liposomes themselves, drop by drop, into the polymer solution, under constant stirring.
  • the formulations for topical use according to the invention will thus comprise the liposomes as described above and will normally be in a form suitable for topical application, such as for example: aqueous solutions, ointments, creams, gels, lotions or polymer films for topical application wherein the liposomes are dispersed using excipients normally used in pharmacopoeia or in cosmetics for the preparation of said formulations.
  • the polymeric films as mentioned above are known and are prepared using organic polymers such as for example: sodium hyaluronate, hydroxypropyl cellulose (HPMC), polyethylene glycol 400 (PEG 400) and water, in appropriate ratios and are characterised in terms of viscoelastic properties, thickness and bioadhesion in vitro respectively using a rheometer, a micrometer and a tensiometer.
  • organic polymers such as for example: sodium hyaluronate, hydroxypropyl cellulose (HPMC), polyethylene glycol 400 (PEG 400) and water, in appropriate ratios and are characterised in terms of viscoelastic properties, thickness and bioadhesion in vitro respectively using a rheometer, a micrometer and a tensiometer.
  • the films are then used for the preparation of medications to be applied topically and consisting for example of strips of various sizes for application onto the skin.
  • the encapsulation efficiency (E%) of PGE1 , carnitine and plant oestrogen in the liposomes was determined by means of HPLC (clearly after having broken down the liposomes with a suitable membrane lysing means, for example with Triton X- 100.)
  • the liposomes are characterised in terms of size, polydispersity index (PI) and zeta potential, while their structural morphological characteristics were studied through transmission electron microscopy (TEM) and polarised light optical microscopy.
  • PI polydispersity index
  • TEM transmission electron microscopy
  • the liposome solution thus obtained is poured into an aqueous solution of polylysine 40 - 100 MW (0.01 mg/10 ml) and constantly stirred for 30 minutes.
  • the solution thus obtained can be used directly on the scalp at least once daily
  • the results of the hair loss cessation can already be observed after just 7 days and the first new hair regrowth results between 45 and 90 days.
  • the ethanol is completely evaporated and the liposomes obtained are placed in contact with 5 ml of a polylysine 40-100 MW (0.01 / 10 ml) solution.
  • the liposome solution thus obtained is poured into an aqueous solution of polylysine 40 - 100 MW (0.01 mg/10 ml) and constantly stirred for 30 minutes then adding 5 ml of buffered water or of saline solution (NaCl 0:9/100 )
  • the diameter of the liposomes was found to be 60 nm on average with polydispersity index equal to 0.2
  • the amount of PGE 1 in the liposomes following purification is in the range of 30- 50 pg/ml while the amount of carnitine is between 0.05 and 0.2 mg/ml.
  • the liposomes were characterised in terms of size, polydispersity index (PI) and zeta potential respectively by means of Photon Correlation Spectroscopy (PCS) (dimensions and PI) and M3-PALS (Phase Analysis Light Scattering), which measures the electrophoretic mobility of the particles in a thermostated cell, (zeta potential) using the Zetasizer nano (Malvern Instrument, UK).
  • PCS Photon Correlation Spectroscopy
  • M3-PALS Phase Analysis Light Scattering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Described herein are liposomes comprising PGE1 in combination with a plant oestrogen and possibly a compound capable of increasing the cationic power of the liposome and their use in the treatment of baldness and hair loss.

Description

LIPOSOMES CONTAINING PROSTAGLANDIN El (PGE1) AND A PLANT OESTROGEN, FORMULATIONS FOR TOPICAL USE CONTAINING THEM AND THEIR USE
Field of the invention
The present invention relates to the field of pharmaceutical and cosmetic formulations for topical use containing liposomes, in particular for the treatment of alopecia and for hair regrowth in general.
Background of the invention
Hair loss is an extremely widespread phenomenon affecting both men and women, caused by various factors such as stress, diet, seasonal changes, hereditary factors, etc.
The phenomenon often has repercussions on the patient such as to make him believe that he has a true pathology and there is, in any case, no doubt as to its impact from an aesthetic point of view.
Many methods are described for the treatment and prevention of baldness, from specific anti-hair loss shampoos, possibly combined with lotion or other products to be applied at more or less regular intervals, to specific pharmacological products (such as Minoxidil or Finasteride).
Nevertheless, despite the many remedies available on the market, the problem is far from being said as satisfactorily resolved.
International patent application WO 2011/095938, in the name of the same Applicant, describes unilamellar liposomes encapsulating PGE1 and/or PGE1-a- cyclodextrin in combination with L-propionyl carnitine, the outer surface of which is coated by hydrophilic polymers useful for the treatment, following systemic administration, of vascular pathologies in diabetic subjects and for the local treatment (topical administration) of skin ulcers and of diabetic retinopathies.
Summary of the invention
Described herein are liposomes encapsulating PGE1 in combination with a plant oestrogen and possibly a compound capable of increasing the cationic power of the liposome
Detailed description of the invention
This invention makes available new pharmacological and/or cosmetic products for the treatment of baldness and hair loss comprising liposomes, encapsulating Prostaglandin E1 (PGE1 ) in combination with a plant oestrogen and possibly a compound capable of increasing the cationic power of the liposome.
The liposomes according to the invention are constituted by a phospholipid vesicle containing a core of aqueous solution.
The phospholipids that constitute the wall of the vesicle are natural or synthetic phospholipids, given their high biocompatibility and the absence of toxicity.
Phospholipids that can be used according to the invention are for example: phosphatidylcholine (lecithin), phosphatidylethano!amine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), palmitoyl-stearoylphosphatidyicholine, sphingomyelin, and the like.
Plant oestrogens shall for example mean: equol and isoflavones in general, such as for example: genistein, daidzein, glycitein.
The function of the compound capable of increasing the cationic power of the liposome is to increase adhesiveness and to also facilitate the endothelial cell metabolism of the micro capillaries; compounds useful for this purpose are, for example, essential amino acids or carnitine, which is also a fatty acid carrier and allows the mitochondria to use them for the production of ATP.
The liposomes can further comprise additives that serve as stabilisers or as modifiers of the surface charge, such as for example cholesterol, cholesterol sulphate and the like.
The liposomes according to the present invention can be prepared by simply mixing solutions of the various components in organic solvent and water, sonicating the mixture thus obtained for the required time.
The organic solvent as indicated above is preferably ethanol.
Alternatively, the mixtures constituted by the solutions of the various components can be sonicated in the organic solvent alone (for example, ethanol) with the organic solvent then being evaporated and re-suspended with an aqueous solution.
In addition, to increase the adhesion of the liposomes to cells of the dermis while avoiding the traumatic removal thereof, the outer surface of the liposomes can be coated with hydrophilic polymers such as for example polylysine, polyornithine, fibronectin and mixtures thereof; preferred is polylysine, which also has bactericidal properties, thus preventing possible infections.
Said coating is obtained by treating the liposomes as described above with an aqueous solution of the hydrophilic polymer as defined above, for example by "dropping" the liposomes themselves, drop by drop, into the polymer solution, under constant stirring.
The formulations for topical use according to the invention will thus comprise the liposomes as described above and will normally be in a form suitable for topical application, such as for example: aqueous solutions, ointments, creams, gels, lotions or polymer films for topical application wherein the liposomes are dispersed using excipients normally used in pharmacopoeia or in cosmetics for the preparation of said formulations.
In particular, the polymeric films as mentioned above are known and are prepared using organic polymers such as for example: sodium hyaluronate, hydroxypropyl cellulose (HPMC), polyethylene glycol 400 (PEG 400) and water, in appropriate ratios and are characterised in terms of viscoelastic properties, thickness and bioadhesion in vitro respectively using a rheometer, a micrometer and a tensiometer.
The films are then used for the preparation of medications to be applied topically and consisting for example of strips of various sizes for application onto the skin. The encapsulation efficiency (E%) of PGE1 , carnitine and plant oestrogen in the liposomes was determined by means of HPLC (clearly after having broken down the liposomes with a suitable membrane lysing means, for example with Triton X- 100.)
The liposomes are characterised in terms of size, polydispersity index (PI) and zeta potential, while their structural morphological characteristics were studied through transmission electron microscopy (TEM) and polarised light optical microscopy.
The invention will now be better illustrated in the light of the following examples. Example 1
Three solutions are prepared as follows: 1 m! of equal is diluted in 1 ml of ethanol and the solution is brought to 10 ml with water;
1 mg of PGE1 in 1 ml of ethanol brought to 10 ml with water;
2 g of carnitine in 10 ml of water.
The above three solutions are placed in a sonicator together with 10 g of phosphatidylcholine (Lipid S75 Human-grade) and sonicated for a sufficient time to obtain liposomes with diameter of less than 100 nm.
The liposome solution thus obtained is poured into an aqueous solution of polylysine 40 - 100 MW (0.01 mg/10 ml) and constantly stirred for 30 minutes. The solution thus obtained can be used directly on the scalp at least once daily The results of the hair loss cessation can already be observed after just 7 days and the first new hair regrowth results between 45 and 90 days.
Example 2
Three solutions are prepared as follows:
1 ml of equol is diluted in 1 ml of ethanol;
1 mg of PGE1 in 1 ml ethanol;
2 g of carnitine in 2 ml of ethanol;
The above three solutions are placed in a sonicator together with 10 g of phosphatidylcholine (Lipid S75 Human-grade) and sonicated for a sufficient time to obtain liposomes with a diameter of less than 100 nm.
The ethanol is completely evaporated and the liposomes obtained are placed in contact with 5 ml of a polylysine 40-100 MW (0.01 / 10 ml) solution. The liposome solution thus obtained is poured into an aqueous solution of polylysine 40 - 100 MW (0.01 mg/10 ml) and constantly stirred for 30 minutes then adding 5 ml of buffered water or of saline solution (NaCl 0:9/100 )
Characterisation of liposomes
The diameter of the liposomes was found to be 60 nm on average with polydispersity index equal to 0.2
The amount of PGE 1 in the liposomes following purification is in the range of 30- 50 pg/ml while the amount of carnitine is between 0.05 and 0.2 mg/ml.
The liposomes were characterised in terms of size, polydispersity index (PI) and zeta potential respectively by means of Photon Correlation Spectroscopy (PCS) (dimensions and PI) and M3-PALS (Phase Analysis Light Scattering), which measures the electrophoretic mobility of the particles in a thermostated cell, (zeta potential) using the Zetasizer nano (Malvern Instrument, UK).

Claims

1. Liposomes comprising prostaglandin E1 in combination with a plant oestrogen and possibly a compound capable of increasing the cationic power of the liposome.
2. Liposomes according to claim 1 comprising natural or synthetic phospholipids selected from: lecithin, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, dimyristoylphosphatidylcholine - DMPC, dipalmitoylphosphatidylcholine DPPC, distearoylphosphatidylcholine DSPC, palmitoyl-stearoylphosphatidylcholine, sphingomyelin possibly in combination with additives that serve as stabilisers or as modifiers of the surface charge.
3. Liposomes according to claim 1 , wherein said plant oestrogen is selected from: equol, isoflavones such as: genistein, daidzein, glycitein.
4. Liposomes according to claim 1 , wherein said compound capable of increasing the cationic power of the liposome is selected from: carnitine and essential amino acids.
5. Liposomes according to claims 1 - 4 on the outer surface of which hydrophilic polymers are present.
6. Liposomes according to claim 5, wherein said hydrophilic polymers are selected from: polylysine, polyornithine, fibronectin and mixtures thereof.
7. A process for preparing liposomes according to claims 1 - 6, wherein solutions in ethanol and water of the various components are mixed, the so obtained mixture is sonicated and optionally the so obtained solution is treated with an hydrophobic polymer in aqueous solution.
8. Process for the preparation of liposomes according to claims 1 - 6, wherein solutions in ethanol of the various components are mixed, the so obtained mixture is sonicated, the solvent is evaporated and the remaining solid is re- suspended with an hydrophobic polymer in aqueous solution.
9. Formulations for systemic topical use comprising the liposomes according to claims 1 - 6.
10. Formulations according to claim 9, consisting of: aqueous solutions, ointments, creams, gels, lotions or polymer films for topical application wherein the liposomes are dispersed.
11.. Formulations according. to claims 9 and 10 for use ί iri the -treatment of'baldness or hair loss.
PCT/IB2013/053912 2012-05-14 2013-05-14 Liposomes containing prostaglandin e1 (pge1) and a plant oestrogen, formulations for topical use containing them and their use WO2013171668A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13731920.8A EP2849714A1 (en) 2012-05-14 2013-05-14 Liposomes containing prostaglandin e1 (pge1) and a plant oestrogen, formulations for topical use containing them and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000092A ITFI20120092A1 (en) 2012-05-14 2012-05-14 LIPOSOMAS CONTAINING PROSTAGLANDIN E1 (PGE1) AND A VEGETAL OTHROGEN, FORMULATIONS FOR TOPICAL USE THAT CONTAIN THEM AND THEIR USE.
ITFI2012A000092 2012-05-14

Publications (1)

Publication Number Publication Date
WO2013171668A1 true WO2013171668A1 (en) 2013-11-21

Family

ID=46208648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/053912 WO2013171668A1 (en) 2012-05-14 2013-05-14 Liposomes containing prostaglandin e1 (pge1) and a plant oestrogen, formulations for topical use containing them and their use

Country Status (3)

Country Link
EP (1) EP2849714A1 (en)
IT (1) ITFI20120092A1 (en)
WO (1) WO2013171668A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015170247A1 (en) 2014-05-06 2015-11-12 Fidia Farmaceutici S.P.A. Liposomes containing di-homo-gamma linolenic acid (dgla), formulations containing them and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040213859A1 (en) * 1999-09-17 2004-10-28 Zelickson Brian D. Organic nutrient for hair loss treatment
US20080275118A1 (en) * 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss
WO2011095938A1 (en) 2010-02-03 2011-08-11 Bioricerca Di Giovanni Brotzu & C. Snc Liposomes containing prostaglandin e1 (pge1), formulations containing them and their use
US20110301105A1 (en) * 2008-09-30 2011-12-08 The Hospital For Sick Children Compositions for proliferation of cells and related methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040213859A1 (en) * 1999-09-17 2004-10-28 Zelickson Brian D. Organic nutrient for hair loss treatment
US20080275118A1 (en) * 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss
US20110301105A1 (en) * 2008-09-30 2011-12-08 The Hospital For Sick Children Compositions for proliferation of cells and related methods
WO2011095938A1 (en) 2010-02-03 2011-08-11 Bioricerca Di Giovanni Brotzu & C. Snc Liposomes containing prostaglandin e1 (pge1), formulations containing them and their use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015170247A1 (en) 2014-05-06 2015-11-12 Fidia Farmaceutici S.P.A. Liposomes containing di-homo-gamma linolenic acid (dgla), formulations containing them and use thereof
EA029823B1 (en) * 2014-05-06 2018-05-31 Фидиа Фармачеутичи С.П.А. Liposomes containing di-homo-gamma linolenic acid (dgla), formulations containing them and use thereof

Also Published As

Publication number Publication date
EP2849714A1 (en) 2015-03-25
ITFI20120092A1 (en) 2013-11-15

Similar Documents

Publication Publication Date Title
Nasr et al. Formulation and evaluation of cubosomes containing colchicine for transdermal delivery
Manconi et al. Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin
Gupta et al. Transfersomes: a novel vesicular carrier for enhanced transdermal delivery of sertraline: development, characterization, and performance evaluation
Manconi et al. Niosomes as carriers for tretinoin. I. Preparation and properties
Parashar et al. Ethosomes: a recent vesicle of transdermal drug delivery system
US20040180082A1 (en) Submicron-liposome containing triterpenoid and a method for preparing the same
Firthouse et al. Formulation and evaluation of miconazole niosomes
US8778367B2 (en) Glycerosomes and use thereof in pharmaceutical and cosmetic preparations for topical applications
HU202745B (en) Process for producing pharmaceutical compositions acting on the skin or percutaneously on the organism, having increased penetration capacity and comprising liposomes as active ingredient carrier
Salerno et al. Lipid-based microtubes for topical delivery of Amphotericin B
JP3011762B2 (en) Medicine
EP2531222B1 (en) Liposomes containing prostaglandin e1 (pge1), formulations containing them and their use
Shelke et al. Ethosomes: a novel deformable carrier
WO2013171668A1 (en) Liposomes containing prostaglandin e1 (pge1) and a plant oestrogen, formulations for topical use containing them and their use
Zaky Comparative study of terbinafine hydrochloride transfersome, menthosome and ethosome nanovesicle formulations via skin permeation and antifungal efficacy
Manconi et al. Penetration enhancer-containing vesicles for cutaneous drug delivery
Thadanki et al. Review on Ethosomes: A novel approach of Liposomes.
EP3145490B1 (en) Liposomes containing di-homo-gamma linolenic acid (dgla), formulations containing them and use thereof
Mohamed et al. Liposomal gels as carriers for safer topical delivery of tazarotene
Patil et al. Ethosome: a versatile tool for novel drug delivery system
EP2255790B1 (en) Liposome composition comprising naproxen, and a method of obtaining same
KR101208120B1 (en) Vitamin complex, preparation methods and cosmetic composition comprising thereof
Nadaf et al. Novel liposome derived nanoparticulate drug delivery system: fabrication and prospects
Bhattacharyya et al. Liposomes as a skin delivery system for cosmeceuticals
Agrawal et al. Formulation, development and evaluation of topical liposomal gel of fluconazole for the treatment of fungal infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13731920

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013731920

Country of ref document: EP